Article
Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer.
Genetic epidemiology - 1 Feb 2021
Sun Ryan, Xu Miao, Li Xihao, Gaynor Sheila, Zhou Hufeng, Li Zilin, Bossé Yohan, Lam Stephen, Tsao Ming-Sound, Tardon Adonina, Chen Chu, Doherty Jennifer, Goodman Gary, Bojesen Stig E, Landi Maria T, Johansson Mattias, Field John K, Bickeböller Heike, Wichmann H-Erich, Risch Angela, Rennert Gadi, Arnold Suzanne, Wu Xifeng, Melander Olle, Brunnström Hans, Le Marchand Loic, Liu Geoffrey, Andrew Angeline, Duell Eric, Kiemeney Lambertus A, Shen Hongbing, Haugen Aage, Johansson Mikael, Grankvist Kjell, Caporaso Neil, Woll Penella, Dawn Teare M, Scelo Ghislaine, Hong Yun-Chul, Yuan Jian-Min, Lazarus Philip, Schabath Matthew B, Aldrich Melinda C, Albanes Demetrios, Mak Raymond, Barbie David, Brennan Paul, Hung Rayjean J, Amos Christopher I, Christiani David C, Lin Xihong
Abstract excerpt
Clinical trial results have recently demonstrated that inhibiting inflammation by targeting the interleukin-1β pathway can offer a significant reduction in lung cancer incidence and mortality, highlighting a pressing and unmet need to understand the benefits of inflammation-focused lung cancer therapies at the genetic level. While numerous genome-wide association studies (GWAS) have explored the genetic etiology...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.